attana - sensor technologies

Drugability determination

The development of successful and well functional drugs without unwanted side effects is a time consuming process involving many risks and high costs.

If the successful drug candidates can be recognized and those of poor quality can be eliminated as early as possible in the discovery process, the risks and costs will decrease whereas the success rate of bringing a new drug to the market will increase. Success in clinical trials is dependent on correct information about the drug candidate and its biological target interaction. Failure, on the other hand, is often due to a lack of relevant information in the selection process.

The Attana biosensors that are based on the mass dependent and proximity independent QCM technology are powerful tools for the improved selection of drug candidates since they have been developed specifically for studying target interactions in their true environment and only those candidates with biologically relevant properties will be selected for downstream in vivo applications. This means that the interactions are studied label-free, under a continuous flow, directly with complex crude biological samples at a physiological temperature and this can be done directly on cells with the Attana Cell 200 instrument to obtain a surrounding as close as possible to the in vivo environment within the biosensor enhancing a faster track to drugabiltiy.